Legacy routinely commissioned policies for drugs now in tariff effective April 2026
- Etanercept and adalimumab for the treatment of deficiency of adenosine deaminase type 2 (aged 5 years and older)
- Biologic therapies for the treatment of juvenile idiopathic arthritis
- Everolimus for subependymal giant cell astrocytoma associated with tuberous sclerosis complex
- Everolimus for refractory focal onset seizures associated with tuberous sclerosis complex (ages 2 years and above)
- Everolimus (Votubia®) for treatment of angiomyolipomas associated with tuberous sclerosis
- Infliximab for refractory sarcoidosis (excluding neurosarcoidosis)
- Infliximab for refractory or progressive neurosarcoidosis (adults and post-pubescent children)
- Rituximab for the treatment of ANCA-associated vasculitis in adults
- Rituximab as a second line agent for the eradication of inhibitors in patients with acquired haemophilia
- Rituximab for second line treatment for anti-NMDAR autoimmune encephalitis (all ages)
- Rituximab for cytopaenia complicating primary immunodeficiency
- Rituximab and eculizumab for the prevention and management of delayed haemolytic transfusion reactions and hyperhaemolysis in patients with haemoglobinopathies
- Rituximab for the treatment of dermatomyositis and polymyositis (adults)
- Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children
- Rituximab for immunoglobulin G4-related disease (IgG4-RD)
- Rituximab for the treatment of IgM paraproteinaemic demyelinating peripheral neuropathy in adults
- Rituximab therapy for the treatment of nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent children
- Rituximab biosimilar for the treatment of myasthenia gravis (adults)
- Rituximab for immunobullous disease
- Rituximab for the treatment of relapsing steroid sensitive nephrotic syndrome
- Rituximab for the treatment of steroid resistant nephrotic syndrome in paediatric patients
- Rituximab for the treatment in acute thrombotic thrombocytopenic purpura (TTP) and elective therapy to prevent TTP relapse
- Addition of rituximab to first-line standard chemotherapy for CD20 positive B-cell precursor acute lymphoblastic leukaemia (adults)
- Sorafenib maintenance for adults with FLT3-internal tandem duplication (FLT3-ITD) acute myeloid leukaemia (AML) undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT)